drugset / Trial / NCT00679523

Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail

NCT00679523

Phase 2 Completed 60 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the safety and efficacy of 5.0% and 7.5% AN2690 Solution in the treatment of distal, subungual onychomycosis of the great target toenail.

Timeline

Start
2005-11
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tavaborole Small molecule 5 % Topical
Subject Tavaborole Small molecule 7.5 % Topical

Indications